Posted by Michael Wonder on 22 Jan 2024
In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property.
22 January 2024 - In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had metastasised into some of his bones.
He welcomed the treatment, but was surprised by the $740 monthly copay cost, even after coverage from Medicare and supplemental insurance.
